osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification - PubMed (original) (raw)
. 1998 May 1;12(9):1260-8.
doi: 10.1101/gad.12.9.1260.
I Sarosi, C R Dunstan, S Morony, J Tarpley, C Capparelli, S Scully, H L Tan, W Xu, D L Lacey, W J Boyle, W S Simonet
Affiliations
- PMID: 9573043
- PMCID: PMC316769
- DOI: 10.1101/gad.12.9.1260
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
N Bucay et al. Genes Dev. 1998.
Abstract
Osteoprotegerin (OPG) is a secreted protein that inhibits osteoclast formation. In this study the physiological role of OPG is investigated by generating OPG-deficient mice. Adolescent and adult OPG-/- mice exhibit a decrease in total bone density characterized by severe trabecular and cortical bone porosity, marked thinning of the parietal bones of the skull, and a high incidence of fractures. These findings demonstrate that OPG is a critical regulator of postnatal bone mass. Unexpectedly, OPG-deficient mice also exhibit medial calcification of the aorta and renal arteries, suggesting that regulation of OPG, its signaling pathway, or its ligand(s) may play a role in the long observed association between osteoporosis and vascular calcification.
Figures
Figure 1
Gene targeting at the OPG locus. (A) Schematic representation of the genomic structure of the murine OPG locus. Restriction sites are indicated as follows: (RI) _Eco_RI; (X) _Xmn_I; (P) _Pst_I. Exons are indicated as black boxes and numbered by Roman numerals. Introns are shown as thin black lines. (B) The targeting vector used to disrupt the OPG gene. The PGK–neo casette was placed in reverse orientation within exon 2, replacing the portion of exon 2 encoding the first 93 amino acids of the mature OPG protein. This strategy effectively eliminates the coding region for the first two cysteine-rich domains of OPG that are required for its activity and places a translation stop codon in-frame, preventing translation of any downstream OPG sequence. (C) The structure of a targeted OPG allele following recombination of the targeting vector at the OPG locus. (D) Southern blot analysis of _Pst_I-digested genomic DNA from wild-type (+/+), heterozygous (+/−), and homozygous (−/−) OPG knockout mice. The wild-type allele is a 2.3-kb _Pst_I fragment, and the targeted allele is a 3.0-kb _Pst_I fragment. The small open box in A and C represents the DNA probe used to screen for recombinant ES cell clones. (E) Northern blot analysis of RNA from offspring derived from heterozygous matings. Ten micrograms of total RNA collected from liver was probed for OPG and β-actin expression. The absence of OPG expression in OPG−/− mice confirmed that OPG is a null allele.
Figure 2
Radiographic analysis of the bones of OPG−/− and wild-type mice. (A,B) Radiographs of 2-month-old female wild-type and OPG−/− mice, respectively. (C,D) Radiographs of the leg, hemipelvis and vertebrae of 2-month-old female wild-type and OPG−/− mice respectively. OPG−/− mice were x-rayed adjacent to wild-type and heterozygous mice using the same x-ray film, to allow for direct comparison of bone density. The strongest phenotype is evident in the vertebrae and long bones. The cortical bone in the femur and pelvis are thinned, and the femoral growth plate is not visible. OPG+/− mice are not different from OPG+/+ mice at this time point. (E) Gross anomalies of the skeleton are seen as early as 1 month after birth in the form of multiple fractures (arrows). (F) Radiograph of 6-month-old female wild-type mouse. (G) Radiograph of 5-month-old OPG−/− female mouse. Note severe deformity of the vertebral column due to the collapse of several vertebral bodies (arrow). This was confirmed by subsequent lateral radiographs of the spine.
Figure 3
Histological evaluation of bone morphology in 7-day and 2-month-old female OPG−/− vs. OPG+/+ mice. (A) OPG+/+ femur; normal femur morphology. (B) OPG−/− femur; note minimal loss of the primary and secondary spongiosa. (C) OPG+/+ femur, cortical area; normal morphology. (D) OPG−/− femur, cortical area, note somewhat increased bone resorption and remodeling. (E) OPG+/+ vertebral body; normal morphology. (F) OPG−/− vertebral body; note osteoporosis characterized by loss of trabecular bone and thinning of the cortical bone. Magnification, 4× in A and B; 30× in C and D; 20× in E and F; H & E stained. (G) OPG+/+ femur; normal femur morphology. (H) OPG−/− femur; note marked loss of the primary and secondary spongiosa, and collapse of the normally rounded articular surface. (I) OPG+/+ femur, cortical area; normal morphology. (J) OPG−/− femur, cortical area; note severe cortical bone porosity with bone resorption and active remodeling. (K) OPG+/+ vertebral body; normal morphology. (L) OPG−/− vertebral body; note severe osteoporosis characterized by loss of trabecular bone and thinning of the cortical bone. Magnification, 4× in G and H; 15× in I and J; 10× in K and L; H & E stained.
Figure 4
Bone remodeling rate, collagen structure, and trabecular density changes in OPG−/− mice. (A,B) TRAP-stained sections (60×) of the metaphyseal region of the proximal humerus showing increased numbers of osteoclasts (arrows) in the OPG−/− (B) compared to OPG+/+ mice (A). (C,D) Polarized light microscopy of cortical bone of the humeral diaphysis showing lamellar collagen deposition in bone of the OPG+/+ (C) compared to the woven pattern in OPG−/− mice (D). (E–G) Von Kossa-stained frozen sections of the proximal tibial metaphysis of 6-month-old OPG+/+, OPG+/−, and OPG−/− mice. Note normal morphology in the OPG+/+ mice (E), lower density in the metaphysis of the OPG+/− mice (F), and even further reduced density in the OPG−/− mice (G). Osteoclast surface as a percent of bone surface (OcS%BS) (H) and osteoblast surface as a percent of bone surface (ObS%BS) (I) are increased in the vertebrae, tibial metaphysis (Tibia MP) and the tibial diaphysis (Tibia DP) of the OPG−/− (solid bars) vs. the OPG+/+ (shaded bars) mice. (*) Different from OPG+/+, P < 0.005. (J) Osteocyte number per mm2 bone area (OtN/BAr) in the tibial diaphysis is increased in OPG−/− vs. the OPG+/+ mice, P < 0.05. (K) Quantitative representation of the trabecular bone density in the metaphyseal region of the tibia expressed as a percent of the total tissue area (BV%TV) in 6-month-old OPG+/+, OPG+/−, and OPG−/− mice. The trabecular bone density was markedly reduced in the proximal tibial metaphysis in the homozygous knockout mice, n = 6, vs. heterozygous mice, n = 9, and wild type mice, n = 7. (*) Significantly lower than wild type, P < 0.001.
Figure 5
Arterial pathology in OPG−/− mice. (A) In situ hybridization with radioactively labeled antisense OPG probe shows high expression of OPG in the incipient part of the aorta of a E18.5 mouse embryo (arrow). Very high signal is detected in a tangential section of the aorta through the smooth muscle wall (arrowhead). (B) OPG expression is also detected by in situ hybridization in the smooth muscle wall of the renal artery of the adult rat. (C) Note normal morphology of a OPG+/+ mouse abdominal aorta; H & E stained, magnification, 4×. (D) Normal morphology of the renal artery of an adult OPG+/+ mouse; H&E stained, 10×. (E) Extensive calcification (arrowhead) in the medial and subintimal region of the ascending aorta of a 2-month-old OPG−/− mouse. Acute dissection of the aortic wall is marked by an arrow; on the opposite wall of the aorta, granulation tissue is present at the site of a former dissection; H & E stained, 2×. (F) Medial/subintimal calcification (arrow) in the renal artery of a 2-month-old OPG−/− mouse with moderate intimal proliferation; H & E stained, 20×.
Similar articles
- Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.
Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Min H, et al. J Exp Med. 2000 Aug 21;192(4):463-74. doi: 10.1084/jem.192.4.463. J Exp Med. 2000. PMID: 10952716 Free PMC article. - RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.
Schoppet M, Preissner KT, Hofbauer LC. Schoppet M, et al. Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):549-53. doi: 10.1161/01.atv.0000012303.37971.da. Arterioscler Thromb Vasc Biol. 2002. PMID: 11950689 Review. - Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. Mizuno A, et al. Biochem Biophys Res Commun. 1998 Jun 29;247(3):610-5. doi: 10.1006/bbrc.1998.8697. Biochem Biophys Res Commun. 1998. PMID: 9647741 - Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis.
Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC. Schoppet M, et al. J Clin Endocrinol Metab. 2004 Aug;89(8):4104-12. doi: 10.1210/jc.2003-031432. J Clin Endocrinol Metab. 2004. PMID: 15292354 - Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P. Collin-Osdoby P. Circ Res. 2004 Nov 26;95(11):1046-57. doi: 10.1161/01.RES.0000149165.99974.12. Circ Res. 2004. PMID: 15564564 Review.
Cited by
- The role and mechanism of protein post‑translational modification in vascular calcification (Review).
Wang D, Li Q, Xie C. Wang D, et al. Exp Ther Med. 2024 Sep 6;28(5):419. doi: 10.3892/etm.2024.12708. eCollection 2024 Nov. Exp Ther Med. 2024. PMID: 39301258 Free PMC article. Review. - RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives.
Monti F, Perazza F, Leoni L, Stefanini B, Ferri S, Tovoli F, Zavatta G, Piscaglia F, Petroni ML, Ravaioli F. Monti F, et al. Int J Mol Sci. 2024 Aug 24;25(17):9193. doi: 10.3390/ijms25179193. Int J Mol Sci. 2024. PMID: 39273141 Free PMC article. Review. - Converging Mechanisms of Vascular and Cartilaginous Calcification.
Gheorghe SR, Crăciun AM, Ilyés T, Tisa IB, Sur L, Lupan I, Samasca G, Silaghi CN. Gheorghe SR, et al. Biology (Basel). 2024 Jul 26;13(8):565. doi: 10.3390/biology13080565. Biology (Basel). 2024. PMID: 39194503 Free PMC article. Review. - The Complex Mechanisms and the Potential Effects of Statins on Vascular Calcification: A Narrative Review.
Kadoglou NP, Stasinopoulou M, Velidakis N, Khattab E, Christodoulou E, Gkougkoudi E, Valsami G. Kadoglou NP, et al. Rev Cardiovasc Med. 2024 Jan 30;25(2):51. doi: 10.31083/j.rcm2502051. eCollection 2024 Feb. Rev Cardiovasc Med. 2024. PMID: 39077343 Free PMC article. Review. - RANKL-mediated osteoclast formation is required for bone loss in a murine model of Staphylococcus aureus osteomyelitis.
Campbell MJ, Bustamante-Gomez C, Fu Q, Beenken KE, Reyes-Pardo H, Smeltzer MS, O'Brien CA. Campbell MJ, et al. Bone. 2024 Oct;187:117181. doi: 10.1016/j.bone.2024.117181. Epub 2024 Jul 1. Bone. 2024. PMID: 38960295
References
- Banks LM, Macsweeney JE, Stevenson JC. Effect of degenerative spinal and aortic calcification on bone density measurements in postmenopausal women: Links between osteoporosis and cardiovascular disease? Eur J Clin Invest. 1994;24:813–817. - PubMed
- Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone. 1996;18:397–403. - PubMed
- Bostrom K, Watson KE, Stanford WP, Demer LL. Atheroclerotic calcification: Relation to developmental osteogenesis. Am J Cardiol. 1995;75:88B–91B. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases